(0)
CHICAGO, April 14, 2021 /PRNewswire/ In-depth analysis and data-driven insights on the impact of COVID-19 included in this global vaccine contract manufacturing market report.
The vaccine contract manufacturing market is expected to grow at a CAGR of approximately 13% during the period 2020-2026.
Key Highlights Offered in the Report:
The global vaccine contract manufacturing market is expected to grow with an incremental growth of around USD 2 billion and absolute growth of around 104% during the forecast period.
In scale of operation, the commercial segment has the highest share of around 64% due to high uptake of vaccines as well as growing vaccine pipeline and is likely to witness highest incremental growth of around USD 1.3 billion during the forecast period.
Pharmaceutical Contract Manufacturing & Contract Market Achieves a New Milestone | Catalent, Pharmaceutical Product Development LLC, AbbVie, Baxter BioPharma Solutions
sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.
Pharmaceutical Contract Manufacturing & Contract Market Achieves a New Milestone | Catalent, Pharmaceutical Product Development LLC, AbbVie, Baxter BioPharma Solutions
texasguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from texasguardian.com Daily Mail and Mail on Sunday newspapers.
Bloomington facility to produce 60 to 90 million doses of Moderna s COVID-19 vaccine
idsnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from idsnews.com Daily Mail and Mail on Sunday newspapers.
Baxter BioPharma Solutions to perform fill/finish services for Moderna’s COVID-19 vaccine Baxter BioPharma Solutions will provide fill/finish sterile manufacturing services and supply packaging for approximately 60-90 million doses of Moderna’s COVID-19 vaccine this year.
The agreement will help Moderna scale up manufacturing capacity in the US as it seeks to reach its target of 1 billion doses globally in 2021.
Manufacture will take place at BioPharma Solutions’ fill/finish sterile manufacturing facilities located in Bloomington, Indiana. The site has capabilities and expertise in parenteral delivery systems and clinical and commercial vaccine manufacturing, including preventive and seasonal vaccines for global markets.